New method for identifying proteins should have “a major impact on the development of new biologics,” U of T researcher says
Biologics are a type of drug that results from the high-tech manipulation of our own proteins, as opposed to more traditional drugs built from synthetic chemicals. Because of their success so far, scientists are racing to create new biologics – and now, a U of T researcher has developed a way to make that process more powerful.
Philip M. Kim, an associate professor in U of T’s Donnelly Centre for Cellular and Biomolecular Research, combined high-tech computer simulation and high-throughput laboratory experiments to create what he hopes will be the most effective way to discover the proteins that are key to new biologics. His research was published online in the journal Science Advances on July 20, 2016.
“A large fraction of new therapeutics these days involve engineered proteins that latch onto a drug target, for instance on a cancer cell,” says Kim, also of the departments of molecular genetics and computer science. “Finding a protein that effectively binds to a target can feel like looking for a needle in a haystack.
“Our method should open up new opportunities to find those key proteins – and make a major impact on the development of new biologics.”
Under the traditional approach to developing a biologic, researchers identify a protein of interest and then test billions of variants, either randomly generated or from a natural source, hoping to find an effective binder. But these methods allow very little control over where and how the protein performs this crucial function on its target – a major factor in its effectiveness.
Kim and his team took a different approach. They used a computer to simulate the binding process, and then designed proteins that would work on the target. This type of theoretical approach has been in development for several decades, but is still not effective enough. So Kim combined the best of both methods. Instead of randomly creating massive libraries of variants, as with the traditional approach, he used computer modelling to generate a smaller, but intelligently designed repertoire of variants. Designing each variant allows for the tight control of all its properties, in contrast to conventional approaches.
“We showed that this method gives you binders that are somewhat stronger than what you get with the conventional approach,” says Kim. “The much smaller library also solves many technical problems, and we can screen for new, previously unscreenable, targets. It’s a very exciting time for cancer research, and for biologics.”
For Kim, the next step is to produce proteins that are important to certain types of cancer, but have not been screened before due to the difficulty producing them.
Learn more: A more powerful way to develop therapeutics?
The Latest on: Biologics
via Google News
The Latest on: Biologics
- Global Diabetic Neuropathy Drugs Market 2019-2023| Development of Novel Biologics to Boost Growth | Technavio on April 17, 2019 at 8:26 am
LONDON--(BUSINESS WIRE)--The global diabetic neuropathy drugs market is expected to post a CAGR of more than 6% during the period 2019-2023, according to the latest market research report by Technavio ... […]
- Lithuanian CDMO adding biologics capacity and more than 60 jobs on April 17, 2019 at 7:40 am
Biologics continue to be a growth area for pharma, and a Lithuanian contract manufacturer intends to get a bigger piece of the market with an expansion that essentially doubles its output and will add ... […]
- FDA's Efforts to Advance the Development of Biologics on April 17, 2019 at 7:40 am
By: Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research CBER Director, Peter Marks, M.D., Ph.D. The FDA’s Center for Biologics Evaluation and Research (CBER) is working at ... […]
- STC Biologics becomes the largest biologics CDMO within five miles of Cambridge, MA after addition of its new GMP manufacturing facility on April 17, 2019 at 7:08 am
NEWTON, Mass., April 17, 2019 /PRNewswire/ -- STC Biologics (www.stcbiologics.com) announced today that it has completed construction of a single-use mammalian GMP manufacturing facility in Newton, ... […]
- ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections on April 17, 2019 at 4:10 am
April 17, 2019 07:08 ET | Source: ADMA Biologics, Inc. RAMSEY, N.J. and BOCA RATON, Fla., April 17, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), today ... […]
- GenSight Biologics Reports Positive Follow-up Results at Week 72 of the RESCUE Phase III Clinical on April 16, 2019 at 10:30 pm
Time Course Visual Acuity, Change from Baseline to Week 72 in ETDRS Letters Equivalent in RESCUE GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma ... […]
- WuXi Biologics Successfully Completed First FDA Routine GMP Inspection on April 16, 2019 at 8:37 pm
SHANGHAI, April 16, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ... […]
- IP Protection for Biologics in the USMCA Incentivizes Future Cures on April 16, 2019 at 8:39 am
Congress is expected to vote on an updated trade agreement with Canada and Mexico in the coming months. The new deal -- the U.S.-Mexico-Canada Agreement -- includes strong intellectual property ... […]
- WuXi Biologics teams up with I-Mab Bio for clinical programs on April 16, 2019 at 5:32 am
WuXi Biologics (OTCPK:WXXWY) and I-Mab Biopharma have entered into a long-term strategic partnership on biologics process development, clinical and commercial manufacturing of I-Mab's highly ... […]
- Global Pharmaceutical Drugs And Biologics Logistics Market Growth Rates, Drivers And Restraint on April 16, 2019 at 2:59 am
LONDON, GREATER LONDON, UK, April 16, 2019 /EINPresswire.com/ -- The global pharmaceutical drugs and biologics logistics market grew from around $70 billion in 2013 to nearly $80 billion in 2017 at an ... […]
via Bing News